Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Enveric BiosciencesENVB -0.69%30 6-1 Month Momentum % is -20.31% as of Sep. 09, 2026. GuruFocus rates ENVB with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,375 Biotechnology companies, Enveric Biosciences ranks worse than 61.75% on this metric.
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2026-09-09), Enveric Biosciences's 6-1 Month Momentum % is -20.31%.
The industry rank for Enveric Biosciences's 6-1 Month Momentum % or its related term are showing as below:
ENVB's 6-1 Month Momentum % is ranked worse than 61.75% of 1375
companies
in the Biotechnology industry
Industry Median: -11.58
vs ENVB: -20.31
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Enveric Biosciences 6-1 Month Momentum % Related Terms
ENVB vs ACXP, HCWB, AAGH: 6-1 Month Momentum % Comparison
For the Biotechnology subindustry, Enveric Biosciences's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enveric Biosciences 6-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Enveric Biosciences's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Enveric Biosciences's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enveric Biosciences (ENVB) has a 6-1 Month Momentum % of -20.31% as of Sep. 09, 2026. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Enveric Biosciences and its competitors. According to the industry distribution chart, Enveric Biosciences ranks #849 out of 1375 companies in the Biotechnology industry, placing it in the top 61.7%.
Is Enveric Biosciences' 6-1 Month Momentum % too high?
Enveric Biosciences' current 6-1 Month Momentum % is -20.31%. Based on the distribution chart, Enveric Biosciences ranks #849 out of 1375 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Enveric Biosciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Enveric Biosciences' 6-1 Month Momentum % compare to ACXP and HCWB?
According to the Biotechnology industry distribution chart, Enveric Biosciences ranks #849 out of 1375 companies for 6-1 Month Momentum %. This places Enveric Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-1 Month Momentum % for a Biotechnology company?
A good 6-1 Month Momentum % depends on the Biotechnology industry context. However, 6-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-1 Month Momentum % mean?
A high 6-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Enveric Biosciences and its competitors. Enveric Biosciences's current 6-1 Month Momentum % is -20.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enveric Biosciences stock overvalued right now?
Enveric Biosciences (ENVB) has a current 6-1 Month Momentum % of -20.31%. The current 6-1 Month Momentum % is -20.31%. Enveric Biosciences' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-1 Month Momentum % calculated?
6-1 Month Momentum % is calculated from a company's financial statements. For Enveric Biosciences (ENVB), the current 6-1 Month Momentum % is -20.31% as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
30GF Score
Get the complete analysis for ENVB
6-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ENVB has been successfully added to your 
